June 17, 2025 01:37 PM EDT
Pharma
FDA+

FDA ap­proves CSL’s pro­phy­lac­tic for se­vere swelling con­di­tion

Nicole DeFeudis

Editor

CSL Behring won FDA ap­proval on Mon­day for its once-month­ly pre­ven­tive treat­ment for a rare, ge­net­ic con­di­tion that caus­es swelling episodes.

An­dem­bry is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

How a tai­lored ALS drug could help broad­en rare dis­ease ther­a­pies

Schol­ar Rock’s mus­cle-pre­serv­ing obe­si­ty drug add-on looks com­pet­i­tive

FDA un­veils one-year pi­lot to speed some new drugs to mar­ket in just one month

CBER head Prasad adds chief med­ical and sci­en­tif­ic of­fi­cer to his ti­tle

Gilead gets ground­break­ing FDA ap­proval for twice-year­ly HIV pre­ven­tion shot 

sponsored

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

A service from the Financial Times